Newsletter · · Ashutosh Agarwal

Managed Care Under Pressure - Week of June 6–13, 2026: MA 2027 Rate Clears +2.5%, V28 Reset Deferred

Managed-care podcast briefing for the week of June 6–13, 2026. CMS finalized a roughly +2.5% 2027 Medicare Advantage rate and shelved the V28 risk-model change to 2028, while enacted federal PBM reform and Medicaid SDP caps deepened the multi-year overhang for UNH, CVS, ELV, CNC and MOH.

Managed Care Under Pressure

Week of June 6–13, 2026: MA 2027 Rate Clears +2.5%, V28 Reset Deferred

The two legs that were missing finally hit tape: the 2027 MA rate and federal PBM reform.

TL;DR

  • The MA leg arrives. An Optum actuary walked through the 2027 Medicare Advantage final rate on a widely-followed payer/provider podcast: ~+2.5% overall reimbursement (vs. flat-to-slightly-negative in the January advance notice), and, critically, CMS did not adopt the proposed risk-adjustment model change after the industry flagged "fundamental technical problems." Net: a reprieve for 2027, but the V28-style reset is "rolling to 2028."
  • The PBM leg goes federal. Pharmacy litigators detailed the 2026 Consolidated Appropriations Act as the most significant federal PBM reform to date: Part D compensation delinked from drug prices, semi-annual transparency reporting to CMS, any-willing-provider teeth, and civil penalties up to $10,000/day. Direct overhang for CVS (Caremark), CI (Express Scripts), UNH (Optum Rx).
  • Medicaid pressure compounds. Fresh detail on HR1's ~$911B/decade Medicaid cut, the work-requirement framework (CMS published the nationwide rule June 1; Nebraska live since May), and SDP caps phasing down 10 points/year from 2028, all negative read-through for Medicaid MCOs (CNC, MOH, ELV) and safety-net hospitals.

This was not a quiet tape. It was the strongest week in over a month for the core thesis, though still sourced from operator/actuarial, legal, and policy voices, not dedicated buy-side or sell-side healthcare investing podcasts.

What's new

1. CMS's 2027 MA final rate, decoded by an Optum actuary, the single most important item this week. On Radio Advisory ep. 302 (June 9), Advisory Board's Abby Burns interviewed Alex Balmes, VP of Actuarial Services at Optum (operator-adjacent / actuarial expert). Balmes confirmed the final rate landed at "about a 2.5% increase in overall MA reimbursement," the effective growth rate ~2.48%, versus the "flat to negative" advance notice that knocked insurer stocks down "as much as 10% to 20% in a single day" in January. The swing factor was risk adjustment: CMS declined to adopt the proposed model after "really good, smart people across the industry" identified "a fundamental problem that led to certain condition categories being over-reimbursed... and the rest under-reimbursed." His warning to the buy side: "Rolling to 2028, plans should be concerned about this is coming. We are going to rebase this model at some point in time." Why it moves numbers: this is the first proper operator/actuarial podcast read on the 2027 MA setup, the exact gap we flagged last week. It confirms 2027 funding is survivable but not stabilizing, with the structural risk-adjustment cut merely deferred, not cancelled. Two other technicals: linked/unlinked chart-review changes were adopted (payer-specific risk-score hits), and the Part D out-of-pocket max rises $2,100 → $2,400.

2. Federal PBM reform stops being a theme and becomes a statute. On the NASP Specialty Pharmacy Podcast / Pharmacy Podcast Network (June 11), Jonathan Schwischer and Bradley Wasser of Duane Morris' Pharmacy Litigation Group (litigation attorneys / policy-legal) broke down the 2026 Consolidated Appropriations Act as "one of the most significant federal PBM reform packages to date." Headline provisions: delinking PBM compensation in Medicare Part D from list price, rebates, and volume-based fees (pushing toward "bona fide flat-fee arrangements"); semi-annual/annual transparency reporting to CMS on rebates, spread pricing, clawbacks, and affiliated-pharmacy arrangements; any-willing-provider/network-access scrutiny; and "civil monetary penalties... up to $10,000 a day for certain violations," enforced across CMS, DOL, HHS, FDA, and Treasury. Why it matters: last week this leg was a Tennessee state law plus a federal bill introduced; this week it is described as enacted federal law that strikes directly at the spread-and-rebate economics underpinning Caremark (CVS), Express Scripts (CI), and Optum Rx (UNH).

3. Medicaid: the financing squeeze gets concrete. On the Becker's Healthcare Podcast (June 6), Dr. Rahul Vanjani (PCP and Eto Health CEO, provider operator) framed HR1 as "the largest Medicaid reduction in U.S. history, about $911 billion in federal Medicaid spending over the next decade" per CBO. The mechanism that hits MCOs is administrative: renewals move from annual to every six months, 80-hour/month work requirements for the expansion population, and retroactive coverage narrowing from three months to one. His historical guide: the unwinding cost "more than 25 million people" their coverage, "a huge share... procedural," and Arkansas's 2018 work requirement dropped 18,000+ in seven months. CMS published the nationwide framework June 1; Nebraska turned requirements on in May (first checks end of July), with Montana, Arkansas, and Iowa following this year.

4. SDP caps, the rate-floor risk for Medicaid plans, phase in faster than headline. On Achieving Health's "Washington Watch" (June 10), regulatory specialists detailed CMS capping state-directed payments at Medicare-equivalent rates, with grandfathered SDPs "reduced by 10 percentage points annually" beginning 2028 until they hit the cap, and the scope expanded "across all SDPs starting in 2029," explicitly including managed-care SDPs. CMS pegs the savings at "approximately $775 billion... over 10 years." This compresses the supplemental layer that props up Medicaid rate adequacy for CNC, MOH, and ELV, and squeezes safety-net hospitals (HCA, THC, UHS, CYH).

5. UNH's coding overhang gets another plaintiff. On Health:Further ep. 193 (June 6), the hosts (investor-pundits) flagged Massachusetts suing UnitedHealthcare for alleged Medicaid fraud, claiming UHC "inflated the sickness of seniors" in MassHealth managed-care plans for "at least $100 million" in improper payments. Their read: "not new... feels like a money grab. And if Massachusetts is going to do it, then every state will do it." Pundit-level, but it keeps the risk-adjustment/RADV/DOJ litigation tail alive for UNH at the state level.

The debate

Bull (utilization/funding has bottomed → margins recover into 2027). The 2027 final rate at +2.5% with the punitive risk-adjustment change withdrawn removes the worst-case scenario that drove the January selloff; insurer stocks already rebounded "5% to 10%" on the final notice (per Radio Advisory's Balmes). MA remains a product members love ("approval ratings... mid to high 90s"), giving operators pricing and benefit-design room as the cycle turns into 2027 repricing.

Bear (structurally higher trend + V28 + political/regulatory pressure = multi-year reset). Balmes was explicit that the rate "doesn't serve to stabilize the MA program longer term" and that the risk-adjustment rebase is coming in 2028, government keeps "levers... to claw back components of MA revenue." Layer on enacted federal PBM reform, Medicaid SDP caps and work requirements draining membership and rate adequacy, and a live state-AG coding suit against UNH, and this looks like a multi-year margin reset, not a one-year air pocket. Balmes' own line: near term, "It puts some companies out of business."

Stocks in play

  • UNH: Bull: 2027 risk-adjustment reprieve, Optum diversification cushions any single line. Bear: Massachusetts coding suit adds to the RADV/DOJ tail; Optum Rx squarely inside enacted PBM delinking; V28 rebase deferred to 2028, not gone. Catalyst: Q2'26 print (MLR vs. guide, FY26 EPS), state-AG procedural updates, PBM rulemaking timeline.
  • CVS: Bull: Aetna MA benefits from the +2.5% 2027 rate and withdrawn risk-adjustment cut. Bear: Caremark is the most exposed name to CAA 2026 delinking, spread-pricing transparency, and any-willing-provider. Catalyst: Q2'26 Aetna MLR, PBM compliance disclosures, strategic-review chatter.
  • HUM: Bull: cleanest 2027 MA leverage; benefits most from the rate reprieve. Bear: highest beta to the 2028 risk-adjustment rebase Balmes flagged. Catalyst: Q2'26 MLR, 2027 bid color. (No company-specific tape this week.)
  • ELV: Bull: Carelon services offset; MA rate relief. Bear: Medicaid SDP cap phase-down (2028) and work-requirement attrition hit the Medicaid book; enhanced-subsidy cliff. Catalyst: Q2'26 Medicaid/MA MLR splits.
  • CNC: Bull: exchange margins; Medicaid acuity reset maturing. Bear: most exposed to SDP cap compression and procedural disenrollment shrinking/souring the risk pool. Catalyst: Q2'26 HBR by segment, state rate updates. (Read-through only.)
  • MOH: Bull: disciplined Medicaid underwriting. Bear: most Medicaid-levered to the SDP cap and work-requirement dynamic. Catalyst: Q2'26 MCR, RFP wins/losses. (Read-through only.)
  • CI: Bull: Evernorth growth, MA exit removed the funding-cycle drag. Bear: Express Scripts inside the federal delinking/transparency frame. Catalyst: Q2'26 Evernorth growth, PBM rulemaking calendar.

Read-throughs

  • Medicaid / exchange insurers (CNC, MOH, ELV): Double hit, work requirements and shorter renewal cycles drive procedural disenrollment (the healthier, easier-to-lose members leave, the sick stay → adverse acuity), while SDP caps compress the supplemental dollars that backstop state rate adequacy from 2028. Watch HBR/MCR by segment into Q2'26.
  • PBMs / Optum-style services arms: CAA 2026 delinking and transparency reporting attack the spread-and-rebate model directly. As FIA Group's Adam Russo put it on Healthcare NOW Radio's "PBM Trap" (June 7), a PBM can mark a $1,000 drug down to $200 and "show 80% savings. Looks like a hero," the economics this reform targets. Structural, not one-quarter, for Caremark/Express Scripts/Optum Rx.
  • Hospitals / providers: The other side of the SDP/site-neutral/price-transparency squeeze, safety-net and rural systems (HCA, THC, UHS, CYH) lose the Medicaid supplemental lift and outpatient premium just as Medicaid coverage erodes and uncompensated care rises.
  • GLP-1 cost exposure: No new investor-grade tape this week. The most-cited GLP-1 episode, DC EKG's "REFILL" (posted June 8), is a rerun originally aired May 2024, useful background (net prices 50%+ below list, ~65% for diabetes-indicated; only ~40% adherence at one year; Lilly direct ~$500/mo vs. ~$1,300 list) but not a fresh signal. Treat as context, not catalyst.

What changed vs. last week

Last week was a policy/PBM tape with the MA leg conspicuously absent. This week filled both gaps the prior edition called out.

  • MA leg, now present: First operator/actuarial podcast read on the 2027 final rate (+2.5%, risk-adjustment cut withdrawn but deferred to 2028), directly answers "still waiting for the MA-funding-vs-trend debate to get tape."
  • PBM leg, escalated: Last week = Tennessee FAIR-RX signed + a federal bill introduced. This week = the 2026 Consolidated Appropriations Act described as enacted federal PBM reform with delinking, transparency, and $10k/day penalties. A material step-change in the overhang for CVS/CI/UNH.
  • SDP caps, sharpened: Last week framed the 100%/110%-of-Medicare cap by 2029. This week added the 10-percentage-point annual phase-down from 2028 and confirmed managed-care SDPs are in scope, faster and broader than the prior framing.
  • UNH litigation: New state plaintiff (Massachusetts) vs. last week's federal DOJ/FTC focus.
  • Still absent: No dedicated buy-side or sell-side healthcare investing podcast; no HUM/ELV/CNC/MOH company-specific guidance or pre-announcements; no Star-ratings litigation update; no Optum-carveout / CVS strategic-review chatter on tape.